个人简介
EducationPh.D. Cardiovascular Institute of Guangdong ProvinceM.D. Sun Yat-sen UniversityAcademic and Professional Experience2016-present Adjunct Professor, Faculty of Health Sciences, University of Macau2016-present Director, Zhuhai People’s Hospital2016-present Chief, Zhuhai Interventional Radiology Center2016-present Post-doctoral Research Associate, Jinan University2014-present Chief, Interventional Radiology Medical Quality Control Center of Guangdong Province2008-2016 Chief, Interventional Radiology Department, Guangdong Provincial People’s Hospital
研究领域
Basic and clinical translational research on malignant tumorPeripheral vascular interventional radiology
近期论文
Representative PublicationsLi M, Fu S, Zhu Y, Liu Z, Chen S, Lu L, Liang C. Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma. Oncotarget 2016, 15;7(11):13248-59.Li M, Xin Y, Fu S, Liu Z, Li Y, Hu B, Chen S, Liang C, Lu L. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study. Medicine 2016;95: e2458.Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial. J Cancer Res Clin Onco 2015 Jun;141(6):1103-8. doi: 10.1007/s00432-014-1866-1.Liu B, Huang JW, Li Y, Hu BS, He X, Zhao W, Zheng YB, Lu LG. Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial. Oncology. 2015;89(1):23-30. doi: 10.1159/000371522.Zhan M, Li Y, Hu B, He X, Huang J, Zhao Y, Fu S, Lu L. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2014 Aug;25(8):1279-1287.e1. doi: 10.1016/j.jvir.2014.04.013Zheng YB, Huang JW, Zhan MX, Zhao W, Liu B, He X, Li Y, Hu BS, Lu LG. Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014;35: 11473-81.Zheng YB, Zhan MX, Zhao W, Liu B, Huang JW, He X, Fu SR, Zhao Y, Li Y, Hu BS, Lu LG. The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Medical oncology 2014;31: 209.Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Medical oncology 2014;31: 843.Fu SR, Zhang YQ, Li Y, Hu BS, He X, Huang JW, Zhan MX, Lu LG, Li JP. Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study. Asian Pacific journal of cancer prevention : APJCP 2014;15: 3151-6.Wu KT, Wang CC, Lu LG, Zhang WD, Zhang FJ, Shi F, Li CX. Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities. World journal of gastroenterology : WJG 2013;19: 3649-57.Li Y, Zheng YB, Zhao W, Liu B, Hu BS, He X, Huang JW, Lu LG. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Medical oncology 2013;30: 730.Zheng YB, Zhao W, Liu B, Lu LG, He X, Huang JW, Li Y, Hu BS. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pacific journal of cancer prevention : APJCP 2013;14: 5527-31.Liang HY, Lu LG, Hu BS, Li Y, Shao PJ. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. Chinese medical journal 2013;126: 4270-6.Chuan-Xing L, Xu H, Bao-Shan H, Yong L, Pei-Jian S, Xian-Yi Y, Xiao-Ning L, Li-Gong L. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer biology & therapy 2011;12: 865-71.Shi M, Lu LG, Fang WQ, Guo RP, Chen MS, Li Y, Luo J, Xu L, Zou RH, Lin XJ, Zhang YQ. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. Journal of the National Cancer Institute 2013;105: 59-68.Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, Yang J, Lu L, Tak WY, Yu X, Lee JH, Lin SM, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology 2014;60: 1697-707.
